## Akira Tamaoka

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/397592/publications.pdf

Version: 2024-02-01

103	1,929	23	39
papers	citations	h-index	g-index
115	115	115	3327 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. Journal of Neurology, 2022, 269, 885-896.	1.8	15
2	Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash. Rheumatology, 2022, 61, 1222-1227.	0.9	32
3	Intertwined vascular skin manifestations in a patient with Sj $\tilde{A}$ $\P$ gren syndrome: A case report. Journal of Cutaneous Immunology and Allergy, 2022, 5, 22-23.	0.2	1
4	Amyloid- $\hat{l}^2$ oligomers interact with NMDA receptors containing GluN2B subunits and metabotropic glutamate receptor 1 in primary cortical neurons: Relevance to the synapse pathology of Alzheimerâ $\in$ Ms disease. Neuroscience Research, 2022, , .	1.0	12
5	Reliability of antinuclear matrix protein 2 antibody assays in idiopathic inflammatory myopathies is dependent on target protein properties. Journal of Dermatology, 2022, 49, 441-447.	0.6	3
6	The identified clinical features of Parkinson's disease in homo-, heterozygous and digenic variants of PINK1. Neurobiology of Aging, 2021, 97, 146.e1-146.e13.	1.5	14
7	Efficacy of bezafibrate for preventing myopathic attacks in patients with very long-chain acyl-CoA dehydrogenase deficiency. Brain and Development, 2021, 43, 214-219.	0.6	5
8	Splice-site mutations in KIF5A in the Japanese case series of amyotrophic lateral sclerosis. Neurogenetics, 2021, 22, 11-17.	0.7	6
9	Fisher syndrome as an immune-related adverse event after using pembrolizumab but not nivolumab. Acta Neurologica Belgica, 2021, 121, 1381-1382.	0.5	2
10	Normocalcemic Primary Hyperparathyroidism Presenting with Muscle Weakness and Body Pain. Internal Medicine, 2021, 60, 953-956.	0.3	1
11	Clinical Application of the Vestibular Stimulation Effect on Balance Disorders with Dementia. Current Alzheimer Research, 2021, 18, 1-7.	0.7	0
12	Transcriptome analysis of gravitational effects on mouse skeletal muscles under microgravity and artificial $1\ g$ onboard environment. Scientific Reports, 2021, $11,9168$ .	1.6	26
13	Cybernic treatment with wearable cyborg Hybrid Assistive Limb (HAL) improves ambulatory function in patients with slowly progressive rare neuromuscular diseases: a multicentre, randomised, controlled crossover trial for efficacy and safety (NCY-3001). Orphanet Journal of Rare Diseases, 2021, 16, 304.	1.2	37
14	Remarkable clinical responses of non-fluctuating Parkinson's disease (PD) after alternating catechol O-methyltransferase inhibitors: case series switching from entacapone 200 ~ 300Âmg/day to opicapone 25Âmg/day. Neurological Sciences, 2021, 42, 4813-4814.	0.9	3
15	Biomolecular Modifications Linked to Oxidative Stress in Amyotrophic Lateral Sclerosis: Determining Promising Biomarkers Related to Oxidative Stress. Processes, 2021, 9, 1667.	1.3	5
16	Familial Mediterranean Fever Is Important in the Differential Diagnosis of Recurrent Aseptic Meningitis in Japan. Internal Medicine, 2020, 59, 125-128.	0.3	6
17	Steroid pulse therapy of radiological disease activity without clinical relapse in CLIPPERS. Neurological Sciences, 2020, 41, 709-711.	0.9	1
18	Radiological findings in siblings with dysferlin mutation with diverse phenotype. Journal of the Neurological Sciences, 2020, 409, 116579.	0.3	0

#	Article	IF	Citations
19	Familial cerebral cavernous malformation presenting with epilepsy caused by mutation in the CCM2 gene. Medicine (United States), 2020, 99, e19800.	0.4	2
20	Amyopathic dermatomyositis combined with peripheral neuropathy. BMJ Case Reports, 2020, 13, e237250.	0.2	2
21	Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis. ENeurologicalSci, 2020, 19, 100236.	0.5	2
22	rAAV8 and rAAV9-Mediated Long-Term Muscle Transduction with Tacrolimus (FK506) in Non-Human Primates. Molecular Therapy - Methods and Clinical Development, 2020, 18, 44-49.	1.8	14
23	Neuron-specific analysis of histone modifications with post-mortem brains. Scientific Reports, 2020, 10, 3767.	1.6	10
24	Deferasirox Might Be Effective for Microcytic Anemia and Neurological Symptoms Associated with Aceruloplasminemia: A Case Report and Review of the Literature. Internal Medicine, 2020, 59, 1755-1761.	0.3	8
25	Clinical features of hemichoreahemiballism: A stroke-related movement disorder. Neurology International, 2020, 12, 8328.	1.3	0
26	Dural Sinus Thrombosis with Nonsymptomatic Persistent Falcine Sinus: A Case Report. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 104309.	0.7	0
27	Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan; 2nd report QOL survey. Molecular Genetics and Metabolism Reports, 2019, 20, 100496.	0.4	7
28	Infectivity Assessment of Recombinant Adeno-Associated Virus and Wild-Type Adeno-Associated Virus Exposed to Various Diluents and Environmental Conditions. Human Gene Therapy Methods, 2019, 30, 137-143.	2.1	8
29	Extracellular RNAs as Biomarkers of Sporadic Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases. International Journal of Molecular Sciences, 2019, 20, 3148.	1.8	37
30	Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review. BMC Neurology, 2019, 19, 263.	0.8	11
31	GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis. Journal of the Neurological Sciences, 2019, 405, 116429.	0.3	14
32	TFEB-mediated Enhancement of the Autophagy-lysosomal Pathway Dually Modulates the Process of Amyloid $\hat{l}^2$ -Protein Generation in Neurons. Neuroscience, 2019, 402, 11-22.	1.1	12
33	Tyrosol Reduces Amyloid-β Oligomer Neurotoxicity and Alleviates Synaptic, Oxidative, and Cognitive Disturbances in Alzheimer's Disease Model Mice. Journal of Alzheimer's Disease, 2019, 70, 937-952.	1.2	25
34	Two distinct prions in fatal familial insomnia and its sporadic form. Brain Communications, 2019, 1, fcz045.	1.5	15
35	Meningeal carcinomatosis presenting with leukoencephalopathy-like imaging findings. ENeurologicalSci, 2019, 14, 21-23.	0.5	0
36	ADAR2-dependent A-to-I RNA editing in the extracellular linear and circular RNAs. Neuroscience Research, 2019, 147, 48-57.	1.0	15

#	Article	IF	Citations
37	Late-onset Transthyretin (TTR)-familial Amyloid Polyneuropathy (FAP) with a Long Disease Duration from Non-endemic Areas in Japan. Internal Medicine, 2019, 58, 713-718.	0.3	2
38	Random Skin Biopsies Before Brain Biopsy for Intravascular Large B-Cell Lymphoma. World Neurosurgery, 2019, 121, e364-e369.	0.7	13
39	Vestibular dysfunction as cortical damage with amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2019, 397, 4-8.	0.3	3
40	Abnormal Saccadic Intrusions with Alzheimer's Disease in Darkness. Current Alzheimer Research, 2019, 16, 293-301.	0.7	9
41	A cerebral phenotype of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids: A case report and review of the literature. Multiple Sclerosis and Related Disorders, 2018, 20, 159-163.	0.9	6
42	ExpansionsÂofÂintronic TTTCA and TTTTA repeats in benign adult familial myoclonic epilepsy. Nature Genetics, 2018, 50, 581-590.	9.4	238
43	Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multiâ€center, openâ€label, 52â€week phase 3 trial. Journal of the Peripheral Nervous System, 2018, 23, 115-119.	1.4	11
44	High-sensitivity quantitative analysis reveals the non-linear relationship between the dose and deposition of diphenylarsinic acid in the rat central nervous system following its subchronic exposure. Neurotoxicology and Teratology, 2018, 65, 26-33.	1.2	4
45	Isolated bilateral abducens paralysis without ptosis in an anti-LDL receptor-related protein 4 antibody-positive patient treated effectively with steroid-pulse therapy. Journal of the Neurological Sciences, 2018, 390, 42-43.	0.3	O
46	Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan. Molecular Genetics and Metabolism Reports, 2018, 15, 55-63.	0.4	22
47	Molecular epidemiological study of familial amyotrophic lateral sclerosis in Japanese population by whole-exome sequencing and identification of novel HNRNPA1 mutation. Neurobiology of Aging, 2018, 61, 255.e9-255.e16.	1.5	37
48	Upbeat nystagmus is a useful sign in the regional diagnosis of trigeminal nerve disorder with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 19, 59-61.	0.9	3
49	Clinical features of drug-induced Parkinsonism. Neurology International, 2018, 10, 7877.	1.3	7
50	Highly Efficient Ultracentrifugation-free Chromatographic Purification of Recombinant AAV Serotype 9. Molecular Therapy - Methods and Clinical Development, 2018, 11, 180-190.	1.8	35
51	Hepatic histopathological changes and dysfunction in primates following exposure to organic arsenic diphenylarsinic acid. Journal of Toxicological Sciences, 2018, 43, 291-298.	0.7	10
52	The effect of truncation on prion-like properties of α-synuclein. Journal of Biological Chemistry, 2018, 293, 13910-13920.	1.6	63
53	Monocular Oculomotor Nerve Disorder Manifesting as Cranial Neuropathy in Systemic Lupus Erythematosus. Internal Medicine, 2018, 57, 3445-3449.	0.3	6
54	Enhancement of the autophagy-lysosomal pathway modulates the process of amyloid $\hat{l}^2$ -protein generation. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-35.	0.0	O

#	Article	IF	CITATIONS
55	Long-term accumulation of diphenylarsinic acid in the central nervous system of cynomolgus monkeys. Archives of Toxicology, 2017, 91, 2799-2812.	1.9	12
56	Transforming growth factor- $\hat{l}^21$ in the cerebrospinal fluid of patients with distinct neurodegenerative diseases. Journal of Clinical Neuroscience, 2017, 35, 47-49.	0.8	13
57	The neurotoxicity of amyloid $\hat{l}^2$ -protein oligomers is reversible in a primary neuron model. Molecular Brain, 2017, 10, 4.	1.3	43
58	Topographical disorientation in a patient with right parahippocampal infarction. Neurological Sciences, 2017, 38, 1329-1332.	0.9	6
59	The neuroprotective effect of perampanel in lithium-pilocarpine rat seizure model. Epilepsy Research, 2017, 137, 152-158.	0.8	23
60	Chronic treatment with a smart antioxidative nanoparticle for inhibition of amyloid plaque propagation in Tg2576 mouse model of Alzheimer's disease. Scientific Reports, 2017, 7, 3785.	1.6	31
61	The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	5.8	182
62	Polymyalgia rheumatica in a melanoma patient due to nivolumab treatment. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1357-1358.	1.2	15
63	Mitochondria are devoid of amyloid $\hat{l}^2$ -protein (A $\hat{l}^2$ )-producing secretases: Evidence for unlikely occurrence within mitochondria of A $\hat{l}^2$ generation from amyloid precursor protein. Biochemical and Biophysical Research Communications, 2017, 486, 321-328.	1.0	23
64	Neuron-specific methylome analysis reveals epigenetic regulation and tau-related dysfunction of BRCA1 in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9645-E9654.	3.3	72
65	Liquorice-induced hypokalaemia in patients treated with Yokukansan preparations: identification of the risk factors in a retrospective cohort study. BMJ Open, 2017, 7, e014218.	0.8	16
66	Polymyositis induced by PD-1 blockade in a patient in hepatitis B remission. Journal of the Neurological Sciences, 2017, 381, 22-24.	0.3	4
67	Paraneoplastic limbic encephalitis with late‑onset magnetic resonance imaging findings: A case report. Molecular and Clinical Oncology, 2017, 7, 259-262.	0.4	1
68	Lateral medullary infarction in a patient with central nervous system lupus. International Journal of Rheumatic Diseases, 2017, 20, 1808-1811.	0.9	0
69	Hemolytic Uremic Syndrome-associated Encephalopathy Successfully Treated with Corticosteroids. Internal Medicine, 2017, 56, 2937-2941.	0.3	9
70	A novel frameshift GRN mutation results in frontotemporal lobar degeneration with a distinct clinical phenotype in two siblings: case report and literature review. BMC Neurology, 2017, 17, 182.	0.8	10
71	Miller Fisher syndrome with sinus arrest. Neurology International, 2017, 9, 7312.	1.3	3
72	The Successful Application of Plasmapheresis in the Treatment of a Patient with Opsoclonus and Autoantibodies to Glutamate Receptor $\hat{\Gamma}$ 2. Internal Medicine, 2017, 56, 2773-2778.	0.3	2

#	Article	IF	Citations
73	A Case of Cerebral Amyloid Angiopathy-related Inflammation with Multiple Microbleeds: Diagnosis by Brain Biopsy. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 820-827.	0.0	O
74	Ultracentrifugation-free chromatography-mediated large-scale purification of recombinant adeno-associated virus serotype 1 (rAAV1). Molecular Therapy - Methods and Clinical Development, 2016, 3, 15058.	1.8	29
75	Vestibular Impairment in Frontotemporal Dementia Syndrome. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 194-204.	0.6	5
76	Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain–Barré syndrome: a case report. Japanese Journal of Clinical Oncology, 2016, 46, 875-878.	0.6	70
77	α-Synuclein Fibrils Exhibit Gain of Toxic Function, Promoting Tau Aggregation and Inhibiting Microtubule Assembly. Journal of Biological Chemistry, 2016, 291, 15046-15056.	1.6	67
78	Adult-onset Krabbe disease presenting as acute hemiparesis and progressive demyelination detected by diffusion-weighted imaging. Journal of the Neurological Sciences, 2016, 367, 326-328.	0.3	4
79	A case of very-long-chain acyl-coenzyme A dehydrogenase deficiency with novel compound heterozygous mutations. Journal of the Neurological Sciences, 2016, 368, 165-167.	0.3	5
80	Third nerve palsy due to local inflammation associated with vascular compression: A case series. Journal of the Neurological Sciences, 2016, 367, 365-367.	0.3	4
81	Decreased dopamine transporter and receptor ligand binding in Parkinsonism with diabetic uremic syndrome. Annals of Nuclear Medicine, 2016, 30, 320-324.	1.2	4
82	Neurodegenerative changes in patients with clinical history of bipolar disorders. Neuropathology, 2015, 35, 245-253.	0.7	28
83	Improvement of gait ability with a short-term intensive gait rehabilitation program using body weight support treadmill training in community dwelling chronic poststroke survivors. Journal of Physical Therapy Science, 2015, 27, 159-163.	0.2	10
84	Vestibular Function Impairment in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 185-196.	1.2	28
85	Amyloid $\hat{l}^2$ -protein oligomers upregulate the $\hat{l}^2$ -secretase, BACE1, through a post-translational mechanism involving its altered subcellular distribution in neurons. Molecular Brain, 2015, 8, 73.	1.3	33
86	LRP1 Downregulates the Alzheimer's β-Secretase BACE1 by Modulating Its Intraneuronal Trafficking. ENeuro, 2015, 2, ENEURO.0006-15.2015.	0.9	16
87	Immunohistochemical characterization of CD33 expression on microglia in Nasuâ€Hakola disease brains. Neuropathology, 2015, 35, 529-537.	0.7	6
88	Amelioration of acylcarnitine profile using bezafibrate and riboflavin in a case of adult-onset glutaric acidemia type 2 with novel mutations of the electron transfer flavoprotein dehydrogenase (ETFDH) gene. Journal of the Neurological Sciences, 2014, 346, 350-352.	0.3	10
89	Detection of diphenylarsinic acid and its derivatives in human serum and cerebrospinal fluid. Clinica Chimica Acta, 2014, 431, 227-231.	0.5	10
90	Sixth nerve palsy associated with obstruction in Dorello's canal, accompanied by nodular type muscular sarcoidosis. Journal of the Neurological Sciences, 2014, 343, 203-205.	0.3	4

#	ARTICLE	lF	CITATIONS
91	Neuronal βâ€amyloid generation is independent of lipid raft association of βâ€secretase BACE1: analysis with a palmitoylationâ€deficient mutant. Brain and Behavior, 2012, 2, 270-282.	1.0	38
92	Pathogenesis of Alzheimer's Disease with Special Reference to Amyloid $\hat{l}^2$ Protein. Nihon Ika Daigaku Igakkai Zasshi, 2012, 8, 285-290.	0.0	0
93	TDP-43 M337V Mutation in Familial Amyotrophic Lateral Sclerosis in Japan. Internal Medicine, 2010, 49, 331-334.	0.3	42
94	Discussions on role of neprilysin and degradating system. Psychogeriatrics, 2004, 4, S13-S18.	0.6	0
95	Discussions on laminin as possible biomarkers for neurodegenerative dementia. Psychogeriatrics, 2004, 4, S39-S44.	0.6	0
96	Discussions on phosphorylated tau and other biochemical markers. Psychogeriatrics, 2004, 4, S45-S50.	0.6	0
97	Plasma levels of amyloid? proteins did not differ between subjects taking statins and those not taking statins. Annals of Neurology, 2001, 49, 546-547.	2.8	39
98	Clinical improvement following interferon-? alone as an initial treatment in CIDP. Muscle and Nerve, 2000, 23, 295-296.	1.0	15
99	Amyloid ? protein species in cerebrospinal fluid and in brain from patients with Down's syndrome. Annals of Neurology, 1999, 46, 933-933.	2.8	22
100	A case of cluster headache associated with mitochondrial DNA deletions (a reply). Muscle and Nerve, 1998, 21, 128-129.	1.0	0
101	Selection of a Suitable Tracheostomy Tube, with Special Reference to Speaking Valve. Japanese Journal of Neurosurgery, 1998, 7, 656-658.	0.0	0
102	Deposition of amyloid $\hat{l}^2$ protein (A $\hat{l}^2$ ) subtypes [A $\hat{l}^2$ 40 and A $\hat{l}^2$ 42(43)] in canine senile plaques and cerebral amyoloid angiopathy. Acta Neuropathologica, 1997, 94, 323-328.	3.9	29
103	Plasma Levels of amyloid ? proteins A?1-40 and A?1-42(43) are elevated in Down's syndrome. Annals of Neurology, 1997, 41, 271-273.	2.8	107